A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

Bone marrow transplants are used to replace damaged blood cells with healthy ones in patients with blood-related conditions.

Orbis Medicines and Vivtex have partnered to support the development of next-generation orally dosable macrocycle drugs.

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

Nura Bio has secured additional $68m in a Series A financing round to advance the development of its neuroprotective ...

The Israeli Ministry of Health granted approval for BeiGene’s TEVIMBRA for unresectable or metastatic oesophageal squamous ...

The partnership will see AI-enabled screening used to address bioavailability issues with Equillium’s cytokine-targeting ...

The company claims that the FTC’s July 2024 report is riddled with “false and misleading claims” about the PBM industry.

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...

Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.

The SBTi has validated and approved India's Piramal Pharma’s near-term greenhouse gas (GHG) emission reduction targets.

The FDA’s RMAT designation for P-BCMA-ALLO1 applies to adult patients with relapsed/refractory multiple myeloma who have ...